Name That Brand: August 2012

Can you name the brand? Each month we print part of a popular pharmaceutical product or advertisement, with clues to its identity. Readers are invited to name the brand for a chance to win a copy of Medicine Avenue II. E-mail your answer to NameThatBrand@haymarketmedia.com or fax 646-638-6150. The deadline is August 31, 2012. The winner will be picked randomly from all correct entries.

Brand X breaks sales boundaries
This politically sensitive and oft-misunderstood drug can be found in the expected places, like chain pharmacies, but is also available from more creative outlets, including at least one university campus vending machine. Despite its hot potato political status, this OTC drug for the over-17 set has augmented branded sales for a company that is mostly known for its prowess in the world of generic drugs, but has taken steps to shore up its brand-name presence.

JUNE's WINNER...
Samantha Hudzina, Project Manager/Traffic Manager at H4B Catapult correctly identified an ad for Amgen's Xgeva, indicated to prevent skeletal-related events in patients with bone metastases from solid tumors.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.